Sarepta Therapeutics (SRPT) Tops Q4 EPS by 84c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of $0.82, $0.84 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $396.78 million versus the consensus estimate of $386.05 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Worried the AI trade has gone too far? Evercore likes these 4 stocks